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Abstract
Background: Mucormycosis has emerged as a rare but frequently fatal invasive fungal disease. Current knowledge
on paediatric mucormycosis is based on case reports and small series reported over several decades. Contemporary
data on a large cohort of patients is lacking.
Methods: Two large international registries (Zygomyco.net and FungiScope™) were searched for mucormycosis
cases in ≤19 year-old patients. Cases enrolled between 2005 and 2014 were extracted, and dual entries in the two
databases merged. Epidemiology, clinical characteristics, diagnostic procedures, therapeutic management and final
outcome were recorded and analysed with SPSS v.12.
Results: Sixty-three unique cases (44 proven and 19 probable) were enrolled from 15 countries (54 in European
and 9 in non-European countries). Median age was 13 years [Interquartile Range (IQR) 7.7] with a slight
predominance (54.1 %) of females. Underlying conditions were haematological malignancies (46 %), other
malignancies (6.3 %), haematopoietic stem cell transplantation (15.9 %), solid organ transplantation, trauma/surgery
and diabetes mellitus (4.8 % each) and a variety of other diseases (7.9 %); in 9.5%, no underlying medical condition
was found. Neutropenia was recorded in 46 % of the patients. The main sites of infection were lungs (19 %), skin
and soft tissues (19 %), paranasal sinus/sino-orbital region (15.8 %) and rhino-cerebral region (7.9 %). Disseminated
infection was present in 38.1 %. Mucormycosis diagnosis was based on several combinations of methods; culture
combined with histology was performed in 31 cases (49.2 %). Fungal isolates included Rhizopus spp. (39.7 %),
Lichtheimia spp. (17.5 %), Mucor spp. (12.7 %), Cunninghamella bertholletiae (6.3 %) and unspecified (23.8 %).
Treatment comprised amphotericin B (AmB) monotherapy in 31.7 % or AmB in combination with other antifungals
in 47.7 % of the cases, while 14.3 % received no antifungals. Surgery alone was performed in 6.3 %, and combined
with antifungal therapy in 47.6 %. Crude mortality at last contact of follow-up was 33.3 %. In regression analysis,
disseminated disease and prior haematopoietic stem cell transplantation were associated with increased odds of
death, whereas the combination of systemic antifungal therapy with surgery was associated with improved survival.
Conclusion: Paediatric mucormycosis mainly affects children with malignancies, presents as pulmonary, soft tissue,
paranasal sinus or disseminated disease and is highly lethal. Outcome is improved when active antifungal therapy
and surgery are combined.
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Background
Mucormycosis in children has emerged as an increas-
ingly important infection and is associated with signifi-
cant morbidity and mortality [1, 2]. Mucorales are
generally characterized by their tendency for rapid vas-
cular invasion leading to vascular thrombosis and tissue
necrosis. As a result, the Mucorales may initially cause
localized infections, but they rapidly progress to invasive
soft tissue, rhinocerebral, orbital, gastrointestinal or pul-
monary infections [2, 3].
Risk factors for mucormycosis in adults include pro-
found and prolonged neutropenia, hematological malig-
nancies, bone marrow or solid organ transplantation,
uncontrolled diabetes mellitus with metabolic acidosis,
iron overload, deferoxamine therapy, previous trauma,
whereas in few cases no apparent underlying condition
can be identified [4–10]. In paediatric reviews, prematur-
ity has also been a risk factor for invasive mucormycosis,
and age <12 months was an independent risk factor for
mortality [1, 11, 12]. While some investigators have
shown an increasing incidence in adults [13], the epi-
demiological data in children are too limited as to pro-
vide epidemiological trends [2]. Due to the rarity of the
disease and the limited awareness of physicians to diag-
nose and record these cases, the true burden in the
paediatric setting is difficult to be estimated.
The aim of this study was to collect and analyse data
of paediatric mucormycosis cases from two international
case registry databases to update and broaden our know-
ledge on epidemiology, clinical characteristics, diagnostic




The study was a combined analysis of prospectively col-
lected cases enrolled in two international invasive fungal
disease (IFD) registries: Zygomyco.net and FungiScope™.
Both databases were searched for invasive infections due
to Mucorales in paediatric (≤19 years) patients. Cases di-
agnosed between 2005 and 2014 were extracted from
the registries and analysed. The selection of the study
period was based on the availability of data in the two
registries.
Zygomyco.net was created in 2004 as a European
registry and later became a global registry for invasive
mucormycosis of the European Confederation of Med-
ical Mycology/International Society for Human and Ani-
mal Mycology (ECMM/ISHAM) Working Group on
Zygomycosis. For this database, a national coordinator
in each participating European country was appointed to
prospectively collect and record confirmed cases in stan-
dardized case report forms (CRFs) at www.zygomyc-
o.net, which were then sent either by e-mail or fax to
the general study coordinator (GP). The national coordi-
nators were internationally recognized experts in the
field of fungal infections, and in most cases they were
appointed by the respective national mycology societies.
Diagnosis of cases was based on standard mycological
tools and when isolate was available by molecular
methods in two central laboratories [9].
FungiScope™ – Global Emerging Fungal Infection
Registry (ClinicalTrials.gov NCT01731353) was created
in 2003 as an international university-based case registry
that collects data of patients with rare IFD, using a web-
based electronic case form at www.fungiscope.net. The
survey was hosted by ClinicalSurveys.net, an internet-
based survey software.
For both databases case registration was on a volun-
tary, non-systematic basis. Data sets were submitted in a
pseudonymized form and regularly checked for com-
pleteness with queries made in written form for missing
data. Follow-up information was repeatedly requested
regarding treatment response, survival or death. If
follow-up could not be continued at all requests, out-
come at last contact was used.
The final analysis of the dataset was performed after
checking for and deleting overlapping cases enrolled in
both registries. The final combined database included
the following variables: gender, age, diagnostic proce-
dures for documenting infection, anatomic location,
underlying conditions, microbiology, management and
outcome.
Definitions
The term mucormycosis was used in this study as a
synonym of zygomycosis [14]. Mucorales are one of the
two orders comprising Zygomycetes, that is Mucorales
and Entomophthorales [14]. In particular, Mucorales
consist of genera including Rhizopus, Mucor, Lichtheimia
(Absidia), Cunninghamella and Saksenaea.
For the present study, a paediatric patient was defined
as an individual ≤19 years of age.
The day of diagnosis was defined as the day on which
the first diagnostic procedure identifying a Mucorales
was performed. For patients with a diagnosis obtained
during post-mortem examination, the day of death was
considered to be the day of diagnosis.
Classification of infection
The sites of infection were classified according to those
utilized in the study of Roden et al. [15]. Accordingly,
dissemination was defined as two or more non-
contiguous locations of Mucorales infection; sino-orbital
disease as involvement of the paranasal sinus and orbit,
without extension to the brain; pulmonary infection as
localised when confined to lung tissue and as deep ex-
tension when invading adjacent tissues. Cutaneous
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infection was characterized as localised when it did not
extend to underlying tissues, in which case it was char-
acterized as having localized soft tissue infection.
For the classification of each case as proven or prob-
able, the revised definitions of IFD of the European
Organization for Research and Treatment of Cancer/
Mycosis Study Group (EORTC/MSG) were used [16].
Proven mucormycosis was defined when both histology
and culture [or polymerase chain reaction (PCR)] existed
and probable mucormycosis when only histology
(proven IFD) or positive culture from a normally non-
sterile site.
Outcome was defined as survival or mortality at last
contact of follow-up. Mortality was assessed as all-cause
mortality during the course of mucormycosis.
Statistical analysis
Statistical analysis was conducted using SPSS v.12. Dif-
ferences between the qualitative variables in two or more
groups were analysed by chi-square test. A two-sided p
value of <0.05 was considered significant. For the esti-
mation of predictors of outcome univariate analysis was
performed using logistic regression for each variable sep-
arately. The variables for which a statistically significant
relationship was shown (p <0.05) were used to construct
a new multivariate model using the logistic regression
approach. In the final regression analysis lost-to-follow
up cases were excluded.
Ethics
Recording patients’ data in the zygomyco.net and analys-
ing them was approved by the Ethics Committee of the
National and Kapodistrian University Attikon General
Hospital located in Athens, Greece, the institution of the
registry principal investigator (reference 9/30-8-2011). In-
formed consent was obtained if required by local laws or
regulations. Ethics Committees that approved data collec-
tion and use for this registry are in Additional file 1.
Similarly, to record patients’ data in FungiScope™ in-
formed consent was obtained if required by local laws or
regulations. The ethics committee at University of Co-
logne, Germany, confirmed the data protection and priv-
acy policy (reference-ID 05-102) [17]. Ethics Committees
that approved the protocol for data collection and use in
the Fungiscope registry are in Additional file 2.
Results
Demographics
During the period 2005–2014, 63 unique paediatric
mucormycosis cases eligible for inclusion were submit-
ted to one or both registries from 15 countries. Thirty-
six were registered in Zygomyco.net, 17 in FungiScope™,
whereas 10 were registered in both registries. Of the
total of 63 cases, 54 cases (85.7 %) were from European
(EU) countries, while 9 cases (14.2 %) were from non-
European countries (non-EU) (Fig. 1). The median age
of the patients was 13 years [Interquartile Range (IQR)
7.7] with a slight predominance of female gender (54.1
%). Age of ≤1 year accounted for 7.9 % of the study
population (5 cases). The median age among EU and
non-EU cases did not show significant difference (13
years vs. 15 years, respectively; p = 0.51).
Underlying conditions
The patients’ underlying conditions are listed in Table 1.
The majority of children had an underlying haemato-
logical malignancy (29 patients, 46 %). Among them,
acute lymphoblastic leukaemia (ALL) was reported in 16
cases, acute myeloid leukaemia (AML) in 11 cases, and
non-Hodgkin lymphoma (T-NHL) as well as myelodys-
plastic syndrome in one case each. Other malignancies
were recorded in four cases (6.3 %): brain tumors in two
cases, and osteosarcoma and thoracic carcinoma in one
case each. At the time of diagnosis, ten patients (15.9 %)
and three patients (4.8 %) had undergone haematopoi-
etic stem cell (HSCT) or solid organ transplantation
(SOT), respectively. Two of the solid organ transplants
included lung. Other underlying conditions (7.9 %) were
two cases of aplastic anaemia and one case each Pear-
son’s syndrome [18], systemic lupus erythematosus and
asplenia. The child with Pearson’s syndrome underwent
therapy with deferoxamine and methylprednisolone on
diagnosis. Diabetes mellitus (DM) alone was present in
three patients (4.8 %), while one patient with T-NHL
presented also a steroid-induced DM at the time of diag-
nosis. Previous traumatic injury or surgery was recorded
in three patients (4.8 %). In one case trauma was in-
duced by a car accident, while surgery was reconstruct-
ive Fallot surgery in two cases. In the remaining six
patients (9.5 %) no underlying medical condition was
found. Neutropenia was reported in 29 (46 %) patients.
The representation of the underlying diseases differed
significantly among EU and non-EU mucormycosis cases
(p = 0.01). The most common underlying disease for the
EU cases was haematological malignancies (35/54; 64.8
%), while for the majority of non-EU cases no underlying
condition was reported (5/9; 55.5 %).
Sites of infection
The anatomic sites of infections and the localization of
infection according to the main underlying condition in
the 63 cases are listed in Table 2. Disseminated infection
at the time of diagnosis was found in 24 (38.1 %) cases.
Dissemination to more than three sites was described in
four cases. Gastrointestinal infection was reported as
part of disseminated disease in nine cases. Other re-
ported locations were pulmonary (localized or with deep
extension) and cutaneous or localized soft tissue
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infections in 12 (19%) cases each, followed by paranasal
sinus plus sino-orbital in 10 (15.9%) and rhinocerebral
in 5 (7.9 %) cases, respectively. Haematological malig-
nancy correlated with pulmonary disease; among 29 pa-
tients with pulmonary focus (alone or part of
disseminated disease), 22 had a haematological malig-
nancy [75.8 %; p = 0.01; Odds Ratio (OR) = 4.4, 95 %
Confidence Intervals (CI) = 1.5-13.3]. Diabetes did not
correlate with rhinocerebral disease, although the num-
ber of patients with DM was small (3 patients). A
significant difference between the site of infection and
the origin of cases was observed. In particular, the most
common site of infection for the EU cases was dissemi-
nated disease (22/54; 40.7 %), while for the non-EU cases
paranasal sinus plus sino-orbital site (5/9; 55.5 %) was
most frequently reported (p = 0.007).
Diagnosis
Diagnostic criteria for mucormycosis are listed in Table 3,
and the causative pathogens are shown in Table 4. In total,
11 different diagnostic methods or combinations of
methods were used for the documentation of mucormyco-
sis. In particular, diagnosis was made only by culture in 11
patients (17.5 %) and by histology in seven patients (11.1
%); both were positive in 12 patients (19 %). Fungal PCR
in addition to culture, histology or direct microscopy was
performed in 11 cases (17.5 %). The combination of direct
microscopy, histology and culture was reported in 12
cases (19%). In two cases the diagnosis of mucormycosis
was made post-mortem at autopsy. Among the 63
pediatric patients enrolled, 44 (69.8 %) were classified as
proven mucormycosis cases and the remaining (30.2 %) as
probable. The most frequently recorded species for EU
and non–EU countries were Rhizopus spp. (26 cases, 46.3
%), followed by Lichtheimia spp. (10 cases, 15.9 %). In 15
patients (23.8 %) Mucorales remained unspecified.
Therapy and outcome
The treatment of mucormycosis is outlined in Table 5.
Of the 63 patients included in the study, four patients
(6.3 %) received no treatment either because diagnosis
Fig. 1 The contribution of European and non-European countries in the paediatric mucormycosis cases of the two registries studied. The names
of the countries are shown in alphabetical order. Dark grey columns represent European countries (EU) while light grey colours represent the
non-EU ones
Table 1 Underlying conditions and associated crude mortality
rates in 63 paediatric patients with invasive mucormycosis
Underlying conditions Cases (%) Mortality (%)f
Haematological malignanciesa 29 (46) 9/23 (39.1)
HSCTb 10 (15.9) 8/10 (80)
SOTc 3 (4.8) 2/2
Other malignanciesd 4 (6.3) 0/3
Diabetes mellitus 3 (4.8) 0/2
Other conditionse 5 (7.9) 0/4
Trauma/surgery 3 (4.8) 1/3
None 6 (9.5) 1/6
a Acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML),
Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL),
myelodysplastic syndrome
b haematopoietic stem cell transplantation
c solid organ transplantation
d Osteosarcoma, thoracic and brain tumour
e Hyposplenism, Pearson syndrome, aplastic anaemia, systemic
lupus erythematosus
f In 10 patients (15.8%) mortality rates were not recorded due to lost to
follow up
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was made post-mortem or patients were lost to
follow-up. Mucormycosis was treated by surgery alone
in four patients (6.3 %). It had successful outcome in
two patients with localized skin and soft tissue infec-
tion, and dismal outcome in two patients with dis-
seminated disease. In total, 25 patients (39.7 %)
received systemic antifungal therapy without surgery.
Another 30 patients (47.6 %) received antifungal ther-
apy and surgery. In patients receiving antifungal ther-
apy, AmB was the first line treatment given either
alone or in combination with other antifungal agents
as shown in Table 6. Monotherapy with AmB was re-
corded in 20 (31.7 %) patients. AmB plus caspofungin
was administered in 4 (6.3 %) patients and AmB plus
micafungin in one patient. AmB plus posaconazole
was administered in 14 patients (22.2 %).
Overall mortality was 33.3 %. In 10 (15.8 %) children
mortality was not recorded because they were lost to follow
up. Mortality did not differ significantly among EU and
non-EU cases (19/45; 42.2 % versus 2/18; 25 %, p = 0.45).
Mortality rates were variable depending on the underlying
condition of the patients, the site of infection, and treat-
ment administered (Tables 7 and 8). The risk factors affect-
ing mortality on univariate analysis were HSCT,
disseminated disease and administration of antifungal drugs
alone, while combined treatment was protective. On multi-
variate analysis, HSCT and dissemination remained inde-
pendent predictors of death.
Table 2 Sites of infection according to the underlying conditions in 63 paediatric cases of mucormycosis
Underlying conditions Dissemination Pulmonary/deep extension Cutaneous + soft tissue Sinus + sinoorbital Rhinocerebral
Haematological malignancies 12/29 (41.3a) 7/29 (24.1) 4/29 (13.7) 4/29 (13.7) 2/29 (6.8)
HSCTb 6/10 (60) 3/10 (30) 1/10 (10) 0 0
SOT 1/3 (33.3) 1/3 (33.3) 1/3 (33.3) 0 0
Other malignancies 2/4 (50) 1/4 (25) 0 0 1/4 (25)
Diabetes mellitus 0 0 1/3 (33.3) 1/3 (33.3) 1/3 (33.3)
Trauma/surgery 1/3 (33.3) 0 2/3 (66.6) 0 0
Other conditions 1/5 (20) 0 2/5 (40) 1/5 (20) 1/5 (20)
None 1/6 (16.6) 0 1/6 (16.6) 4/6 (66.6) 0
Total
Number of cases (%) 24 (38.1) 12 (19) 12 (19) 10 (15.9) 5 (7.9)
Mortality (%) 13/21 (61.9) 3/10 (30) 0/9 (0) 4/10 (40) 1/3 (33.3)
HSCT hematopoietic stem cell transplantation, SOT solid organ transplantation
a Numbers in parenthesis are percentages
b In 10 patients (15.8%) mortality rates were not recorded due to lost to follow up
Dissemination was defined as >1 non-contiguous locations of Mucorales infection
Pulmonary infection was characterized as localized when it was only in the lung tissue and with deep extension when it extended to adjacent tissues, such as
pleura and heart
Sino-orbital refers to cases involving sinus and orbit, without extension to brain
Table 3 Various diagnostic methods of paediatric
mucormycosis cases
Diagnostic method(s) used Cases (%)
Culture 11 (17.5)
Histology 7 (11.1)
Direct microscopy 1 (1.6)
Histology + direct microscopy 6 (9.5)
Histology + culture 12 (19)
Direct microscopy + culture 3 (4.8)
PCRa + histology 2 (3.2)
PCR + culture 2 (3.2)
Direct Microscopy + Histology + Culture 12 (19)
Histology + culture + PCR 3 (4.8)
Direct Microscopy + Histology + Culture + PCR 4 (6.3)
a PCR: polymerase chain reaction
Table 4 Causative pathogens identified in 63 pediatric patients
with invasive mucormycosis
Pathogen Cases (%) Mortality (%)
Rhizopus spp.: 26 (41.3) 11/24 (45.8)
R. oryzae 8 3/7 (42.8)
R. microsporus 4 3/4 (75)
R. homothallicus 1 0/1
Unspeciated 13 5/13 (38.4%)
Lichtheimia spp.: 10 (15.9) 4/8 (50)
L. corymbifera 7 2/6 (33.3)
L. ramosa 2 1/2 (50)
Unspeciated 1 1/1 (100)
Mucor spp. 8 (12.7) 0/7 (0)
Cunninghamella spp. 4 (6.3) 1/3 (33.3)
Unidentified Mucorales 15 (23.8) 5/11 (45.4)
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Discussion
This is the largest multinational analysis of contempor-
ary data of paediatric mucormycosis cases based on elec-
tronic recording in two independent global registries.
Based on the results of the present study, mucormycosis
in children seems to be a rather heterogeneous infec-
tious disease as far as mortality rate is concerned. This is
directly associated with the dissemination of the infec-
tion and the underlying condition of the patients. In par-
ticular, although the crude mortality rate for the whole
paediatric cohort was 33.3 %, the percentage of children
who died with disseminated mucormycosis was signifi-
cantly higher (61 %) compared to the children with lo-
calized disease (0 %). Furthermore, in children suffering
from malignancies the mortality rate ranged from 41.3 %
to 66.6 %, while in children without any underlying con-
dition the mortality rate was relatively low (16.6 %). The
multivariate analysis confirmed the observations of the
initial descriptive analysis revealing that two of the main
independent significant factors influencing mortality in
paediatric mucormycosis were disseminated infection
and HSCT. These results emphasize the need for high
awareness and prompt diagnosis especially during severe
immunocompromise. Mucorales rapidly invade vessels
and disseminate, thus antifungal therapy combined with
surgical debridement significantly impacted on mortality
in our multivariate analysis. Irrespective from other con-
founding variables, children receiving antifungal therapy
and surgery had a mortality rate of 18.5 %, while patients
receiving antifungal therapy alone or no therapy at all
reached a mortality rate of 60 % and 100 %, respectively.
The abovementioned results should be interpreted with
caution since the rather small sample size of the children
precluded weighing for potential confounding factors.
Haematological malignancies and HSCT predominated
as underlying conditions. DM was present in only 5 %,
while in 10 % of the children no predisposing factor was
identified. The predominance of immunocompromised
patients could be explained either by increase of the fre-
quency of such children worldwide or by reporting bias
and increased awareness of haematology centers to par-
ticipate and include cases in registries. In the largest
subgroup of immunocompromised children, as depicted
in Table 2, disseminated and pulmonary infection were
found, in concordance with previous literature, as the
most frequent sites of infection. By comparison, local-
ized skin and soft tissue infections or sinus infections
were more frequently detected in cases associated with
trauma/surgery or without any underlying condition [1,
2, 9, 10, 19]. DM was not associated with rhinocerebral
mucormycosis possibly due to the small number of DM
cases [9, 15, 19]. In a previous review article,
Table 5 Treatment and outcome of 63 paediatric patients with
invasive mucormycosis
Treatment Cases (%) Mortality (%)a
Surgery and antifungal drugs 30 (47.6) 5/27 (18.5)
Only antifungal treatment 25 (39.7) 12/20 (60)
Only surgery 4 (6.3) 2/4 (50)
No treatment 4 (6.3) 2/2 (100)
a In 10 patients (15.8%) mortality rates were not recorded due to lost to
follow up
Table 6 Antifungal drug treatments with or without surgery
Antifungal treatment Cases (%) Mortality (%)
AmB 20 (31.7) 4/17 (23.5)
AmB + POSa 14 (22.2) 3/14 (21.4)
AmB + CASb 4 (6.3) 2/3 (66.6)
AmB + VORIc + CAS + POS 2 (3.2) 0/1
AmB + CAS + FLUd 1 (1.6) 1/1
CAS 2 (3.2) 1/1
CAS + VORI 2 (3.2) 2/2
AmB + MICe 1 (1.6) 0/1
AmB + VORI 1 (1.6) 0/1
POS + FLU + CAS 1 (1.6) 1/1
POS 1 (1.6) not reported, NR
aPOS: posaconazole; bCAS: caspofungin; cVORI: voriconazole; dFLU: fluconazole;
eMIC: micafungin
Table 7 Univariate analysis of risk factors for mortality
Variables Death rate (%) p-value OR (95% CI)a
Female gender 11/28 (39.2) 0.991
Age < 5 years 3/10 (30) 0.687
Haematological disorder 15/31 (48.3) 0.121
AMLb 5/11 (45.4) 0.736
HSCTc 8/10 (80) 0.009 2.6 (1.5–4.5)
Neutropenia 13/26 (50) 0.166
No underlying condition 1/6 (16.6) 0.384
Dissemination 13/21 (61) 0.0085 2.47 (1.2–4.9)
Trauma/Surgery 1/3 (33.3) 0.819
Combined treatment 5/27 (18.5) 0.002 0.3 (0.12–0.7)
Only antifungal treatment 11/19 (57.8) 0.042 1.9 (1–3.7)
a OD: Odds Ratio; CI: Confidence intervals
b AML: Acute myeloid leukemia
c HSCT: Hematopoietic stem cell transplantation
Table 8 Multivariate analysis of risk factors for mortality
Variables p-value OR (95% CI)a
HSCTb 0.01 13.66 (1.88–98.9)
Only antifungal treatment 0.271 2.3 (0.5–10.6)
Combined treatment 0.035 0.37 (0.1–0.9)
Disseminated infection 0.05 4.2 (0.9–18.5)
a OD: Odds Ratio; CI: Confidence intervals
b HSCT: Hematopoietic stem cell transplantation
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gastrointestinal (GI) infections accounted for almost 20
% of children with mucormycosis, but the majority of
these patients were neonates, in which the final diagno-
sis was placed post-mortem [1]. This might have led to
underrepresentation of this patients’ group in the regis-
tries of the present study. However, we observed few GI
infections recorded as part of disseminated disease, possibly
due to delay in diagnosis of mucormycosis. Additionally,
the median age in the review [1] was 5 years with a respect-
able number of infants, while the median age in our registry
study was 13 years with a small proportion of cases below
one year of age (8 %). Irrespectively of the exact percentages
of underlying conditions it is important to emphasize that
infections due to Mucorales are observed in rather hetero-
genic paediatric populations with a wide spectrum of organ
involvement and subsequently with significant differences
in treatment approach and outcome.
The distribution of Mucorales revealed that Rhizopus
spp. remains the most frequent species isolated in chil-
dren, followed by Lichtheimia spp. Of interest, in a pre-
vious systematic review of published paediatric cases,
the second most frequent specie isolated was Mucor sp.
[1]. According to a recent epidemiological study by Lan-
ternier et al. the prevalence of Lichtheimia spp. in Eur-
ope ranges from 18 % to 24 %, while in similar studies
from Asia and the US Lichtheimia spp. are recorded
with a frequency of <10 % [19]. In our study, the major-
ity of data derived from European countries (54 cases)
and the percentage of Lichtheimia spp. recorded was al-
most 16%. Based on this information, the percentage of
Lichtheimia spp. in our study may not directly reflect an
actual epidemiological rise of these species in children.
However, it may represent different fungal biogeography
distribution among European and non-European coun-
tries that needs further confirmation with extended ana-
lysis of the local fungal niches worldwide.
Treatment options against mucormycosis consisted
mainly of combined therapy (antifungal therapy and sur-
gery) recorded in 47.6 % or of antifungal therapy alone
reported in almost 40 % [9, 20]. Amphotericin B was the
drug of choice given either as monotherapy (31.7 %) or
in combination with other antifungal agents. The super-
iority of AmB monotherapy or combination therapy
compared to other therapeutic options against Mucor-
ales infections was observed in a previously published
study with solid organ transplantation (SOT) patients
suffering from mucormycosis. This study concluded that
AmB might influence overall survival. However, in other
studies the choice of first line antifungal therapy did not
significantly influence the survival rates of the patients
[9, 10, 19]. In our study, the impact of AmB as mono-
therapy or combined with other antifungals on overall
survival could not be estimated, because the number of
patients taking the various antifungals with AmB was
too small and a statistical comparison was not feasible.
In addition, concomitant confounding factors hindered
further analysis of the present data. On the other hand,
in our study combined antifungal therapy plus surgery
remained an independent factor for survival. Results
from previous studies are rather controversial. One
study showed that surgery in adult patients does not sig-
nificantly influence overall survival, while other studies
stressed that surgery alone improves outcome, especially
in SOT patients [1, 9, 15, 19, 21]. We can hypothesize
that in localized infections surgery improves outcome by
hindering dissemination, while in severely sick patients,
combination of antifungal drugs plus surgery signifi-
cantly reduces the overall burden of disease.
In the present study, further independent risk factors
for mortality were dissemination and HSCT. These re-
sults are in concordance with previous data [19]. Thus,
age <12 months was also an independent risk factor for
mortality in paediatric patients, which was not the case
in our case series, although these differences may also be
partially explained by the significant differences in the
median age of the children [1, 9, 19]. The overall mortal-
ity rate was 33.3 %. As expected, the mortality rates pre-
sented great variability among different anatomic sites
and underlying conditions. In particular, localized infec-
tion and no underlying conditions or trauma presented
the highest survival rates, while disseminated infection
and HSCT were associated with increased mortality rate.
Limiting factors of the present study were associated
with the nature of its design that was based on the ex-
traction and evaluation of data from two differently or-
ganized global registries. This has led to the collection
and careful analysis only of variables/data with exactly
the same characteristics, such as definitions, stratifica-
tions, data recorded. For that reason clinical presenta-
tion of the cases as well as epidemiological time trends
of paediatric mucormycosis were not analysed in the
present study. A correlation between the specific coun-
tries and the variables presented in the study could be
very useful to detect possible differences among cases
worldwide. It is probable that the number of mucormy-
cosis cases in each country in the present study does not
necessarily reflect the country-specific rates of the dis-
ease, but the awareness of the investigators to report the
cases in the two databases. Additionally, several coun-
tries reported only one to two cases during the study
period therefore a statistical analysis between the vari-
ables and the specific counties was not feasible. In an at-
tempt to detect differences in pediatric mucormycosis
cases between EU and non-EU countries our analysis
showed that there was no statistical difference reported
as far as age, causative pathogens and survival is con-
cerned. This result should be interpreted with caution
since the number of non-EU cases was small to draw
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conclusions. On the other hand, due to the rarity of the
disease, previous data from the literature until now were
mainly extracted from i) mixed adult-children popula-
tion databases with a limited number of paediatric cases,
ii) very small paediatric case series or iii) literature re-
view analyses [1, 2, 9, 10, 12]. In that sense, this is a first
time of prospectively collecting and analysing global
contemporary cases of mucormycosis in children.
One of the major strengths of the present study is the
“merging” of data in order to obtain a satisfactory
pediatric sample. This is prerequisite in order to obtain
results with sufficient statistical power and to draw con-
clusions for rare fungal diseases. Beyond the limitations
mentioned, the present study increases the degree of
awareness of this potentially fatal disease among physi-
cians and offers further important information enriching
our knowledge on epidemiology and current manage-
ment of invasive mucormycosis in the paediatric setting
from two international databases.
Conclusions
This is an epidemiologic study analysing a large number
of invasive mucormycosis contemporary cases in paedi-
atric patients prospectively recorded in two international
registry databases. Mucormycosis mainly affects children
with malignancies or HSCT and presents as dissemi-
nated or pulmonary infection. Mortality is improved
when active antifungal therapy and surgery are
combined.
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